JP2014523445A - 前立腺癌を処置するための新規な組成物及び方法 - Google Patents

前立腺癌を処置するための新規な組成物及び方法 Download PDF

Info

Publication number
JP2014523445A
JP2014523445A JP2014521743A JP2014521743A JP2014523445A JP 2014523445 A JP2014523445 A JP 2014523445A JP 2014521743 A JP2014521743 A JP 2014521743A JP 2014521743 A JP2014521743 A JP 2014521743A JP 2014523445 A JP2014523445 A JP 2014523445A
Authority
JP
Japan
Prior art keywords
composition
compound
solid dispersion
solid
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523445A5 (enExample
Inventor
ケースビアー，デイビッド，スコット
センティッシ，アブデラ
モアトン，リチャード，クリスチャン
ターンブル，マーク
Original Assignee
トーカイ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トーカイ ファーマシューティカルズ，インク． filed Critical トーカイ ファーマシューティカルズ，インク．
Publication of JP2014523445A publication Critical patent/JP2014523445A/ja
Publication of JP2014523445A5 publication Critical patent/JP2014523445A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014521743A 2011-07-18 2012-07-18 前立腺癌を処置するための新規な組成物及び方法 Pending JP2014523445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508823P 2011-07-18 2011-07-18
US61/508,823 2011-07-18
PCT/US2012/047253 WO2013012959A1 (en) 2011-07-18 2012-07-18 Novel compositions and methods for treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2014523445A true JP2014523445A (ja) 2014-09-11
JP2014523445A5 JP2014523445A5 (enExample) 2015-09-03

Family

ID=47558457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521743A Pending JP2014523445A (ja) 2011-07-18 2012-07-18 前立腺癌を処置するための新規な組成物及び方法

Country Status (8)

Country Link
US (3) US20140288037A1 (enExample)
EP (1) EP2734207A4 (enExample)
JP (1) JP2014523445A (enExample)
CN (1) CN103813794A (enExample)
AU (1) AU2012284053A1 (enExample)
BR (1) BR112014001440A2 (enExample)
CA (1) CA2841960A1 (enExample)
WO (1) WO2013012959A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534320A (ja) * 2017-09-22 2020-11-26 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
KR20180099916A (ko) 2007-02-09 2018-09-05 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP3153501B1 (en) 2008-08-13 2018-11-28 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
CA2902971A1 (en) 2013-03-12 2014-09-18 Patheon, Inc. Drug delivery system
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
EP2969227B1 (en) * 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
WO2014165815A2 (en) * 2013-04-04 2014-10-09 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
KR20160058774A (ko) * 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US10045998B2 (en) 2013-12-12 2018-08-14 Basf Se Solid form of abiraterone acetate
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
US9937259B2 (en) * 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
WO2016057839A1 (en) * 2014-10-08 2016-04-14 Boston Biopharm, Inc. Compositions and methods for increasing the bioavailability of one or more compounds
CN105616365B (zh) * 2014-11-08 2019-04-05 山东新时代药业有限公司 一种依维莫司片剂
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2016172517A1 (en) * 2015-04-24 2016-10-27 Tokai Pharmaceuticals, Inc. Methods of treating prostate cancer
US10550107B2 (en) 2015-05-18 2020-02-04 Msn Laboratories Private Limited Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
CN106692051B (zh) * 2015-08-18 2021-01-12 南京诺瑞特医药科技有限公司 17-（3-吡啶）雄甾-4,6-二烯-3-酮的制剂
CN105055314A (zh) * 2015-09-28 2015-11-18 杭州安德科技有限公司 一种阿比特龙的口腔喷雾剂及其使用和制备方法
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
CN110636837B (zh) * 2017-08-28 2022-05-24 江苏恒瑞医药股份有限公司 一种cyp17抑制剂的药物组合物及其制备方法
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
CN109956990B (zh) * 2017-12-22 2023-02-17 四川科瑞德制药股份有限公司 一种干燥哌库溴铵的方法
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
PL247245B1 (pl) * 2019-01-31 2025-06-02 Gdanski Univ Medyczny Samoemulgująca kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym
CN110917152B (zh) * 2019-02-01 2021-07-02 鲁南制药集团股份有限公司 一种cyp17抑制剂片及其制备方法
CZ2019168A3 (cs) 2019-03-20 2020-09-30 Zentiva, K.S. Farmaceutická kompozice obsahující abirateron acetát
CN110538150A (zh) * 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
WO2021094992A1 (en) * 2019-11-14 2021-05-20 Suven Life Sciences Limited Amorphous pharmaceutical compositions of abiraterone acetate
BR112022021040A2 (pt) * 2020-04-16 2022-12-06 Tavanta Therapeutics Hungary Incorporated Métodos e composições para o tratamento de câncer de próstata
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
WO2024091899A1 (en) * 2022-10-25 2024-05-02 University Of Maryland, Baltimore Salts of galeterone and salts of next generation galeterone analogs, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521963A (ja) * 2001-10-15 2004-07-22 アストラゼネカ・ユーケイ・リミテッド 医薬製剤
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
DE69942721D1 (de) * 1998-04-10 2010-10-14 Mitsubishi Chem Corp Sialsäure-derivate enthaltende feste dispersion
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
MX2007010593A (es) * 2005-03-02 2008-02-20 Univ Maryland Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
WO2010089763A2 (en) * 2008-06-30 2010-08-12 Reliance Life Sciences Pvt. Ltd. Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521963A (ja) * 2001-10-15 2004-07-22 アストラゼネカ・ユーケイ・リミテッド 医薬製剤
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYAN,C.J. ET AL, JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 9, JPN6016017632, 2010, pages 1481 - 1488, ISSN: 0003316198 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534320A (ja) * 2017-09-22 2020-11-26 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法

Also Published As

Publication number Publication date
WO2013012959A1 (en) 2013-01-24
EP2734207A1 (en) 2014-05-28
AU2012284053A1 (en) 2014-01-23
US20140288037A1 (en) 2014-09-25
US20150320770A1 (en) 2015-11-12
US20160002283A1 (en) 2016-01-07
BR112014001440A2 (pt) 2017-02-21
CA2841960A1 (en) 2013-01-24
CN103813794A (zh) 2014-05-21
EP2734207A4 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
JP2014523445A (ja) 前立腺癌を処置するための新規な組成物及び方法
CN113518616B (zh) 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
TWI482768B (zh) 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
US12171770B1 (en) Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters
KR102606253B1 (ko) 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
JP2016074687A (ja) 前立腺癌の処置
JP2003507327A (ja) 化学化合物
CA2672888A1 (en) Methods and formulations for improved bioavailability of antiprogestins
JP7241807B2 (ja) １５β－ヒドロキシ－酢酸オサテロンの結晶多形
KR20170129785A (ko) Olig2 활성의 억제
JP2022078094A (ja) Ｏｌｉｇ２活性の阻害
WO2005046697A1 (ja) フェニルアラニン誘導体の徐放性経口投与製剤
WO2012127495A2 (en) A pharmaceutical composition and process for preparation thereof
KR100816960B1 (ko) 2,5-디메틸-2ｈ-피라졸-3-카르복실산｛2-플루오로-5-[3-((ｅ)-2-피리딘-2-일-비닐)-1ｈ-인다졸-6-일아미노]-페닐｝-아미드의 다형성 및 무정질 형태
JP2010519312A (ja) 薬学的製剤
CN108779142A (zh) 选择性孕酮受体调节剂(SPRM) (11.β.,17.β.)-17-羟基-11-[4-(甲基磺酰基)苯基]-17-(五氟乙基)雌甾-4,9-二烯-3-酮的前药
CN101830911B (zh) 一类噻吩并吡啶衍生物、其制备方法和用途
KR20230024389A (ko) 우티델론의 고체 경구용 제제
JP2022000473A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
JP2025538466A (ja) ５－［（２，４－ジニトロフェノキシ）メチル］－１－メチル－２－ニトロ－１ｈ－イミダゾールの結晶性形態
BR122023016197B1 (pt) Sal cristalino de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida, composição farmacêutica o compreendendo e uso dos mesmos
CN101317848A (zh) 依匹乐酮晶形

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170206